Altimmune to Participate in the Leerink Global Healthcare Conference

Group 1 - Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics [2] - The company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist aimed at treating obesity and MASH [2] - Management will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2025, at 3:40 p.m. EST, which will be webcast [1] Group 2 - The conference details can be accessed through the Events section of the Altimmune website [1] - Contact information for the company's Chief Financial Officer and investor relations is provided for further inquiries [2]